Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
30 hedge funds and large institutions have $3.5M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 7 closing their positions.
14% less funds holding
Funds holding: 35 → 30 (-5)
52% less capital invested
Capital invested by funds: $7.33M → $3.5M (-$3.83M)
62% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 13
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$61.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$38.6K |
| 3 |
AI
Atom Investors
Austin,
Texas
|
+$5.51K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.96K |
| 5 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
+$3.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$434K |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$314K |
| 3 |
Two Sigma Advisers
New York
|
-$63.5K |
| 4 |
Millennium Management
New York
|
-$59K |
| 5 |
BlackRock
New York
|
-$49.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| $132 | – | – | – |
|
|
BRWM
27
B. Riley Wealth Management
Memphis,
Tennessee
| $10 | – | – | – |
|
|
NCM
28
Nantahala Capital Management
New Canaan,
Connecticut
| – | -$434K | -19,369 | Closed |
|
|
29
Millennium Management
New York
| – | -$59K | -2,647 | Closed |
|
30
Group One Trading
Chicago,
Illinois
| – | -$27.2K | -1,968 | -100% |
|
31
Two Sigma Investments
New York
| – | -$13K | -577 | Closed |
|
32
UBS Group
Zurich,
Switzerland
| – | -$12K | -546 | Closed |
|
|
VF
33
Virtu Financial
New York
| – | -$11K | -513 | Closed |
|
34
Jane Street
New York
| – | -$11K | -509 | Closed |
|
35
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$4.1K | -297 | Closed |
|
36
Simplex Trading
Chicago,
Illinois
| – | -$235 | -17 | -89% |
|
37
JP Morgan Chase
New York
| – | -$207 | -15 | -94% |
|
ELOX Hedge Fund Activity: Q2 2022 in Review
30 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q2 2022, worth a combined $3.5M — down 52% from $7.33M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ELOX and 2 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $61.9K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $434K sold.
- 30 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q2 2022, down from 35 in Q1 2022.
- Funds reported $3.5M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 52% quarter-over-quarter.
- 2 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 7 closed out, a net change of -5 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Renaissance Technologies, an estimated $61.9K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Nantahala Capital Management, an estimated $434K sold.
Based on aggregated 13F filings for Q2 2022.